Studies on changes in serum butyrylcholinesterase activity of rivastigmine transdermal preparation in Alzheimer's type dementia patients and its effect on cognitive function, lipid / blood pressure / sugar metabolism
Not Applicable
- Conditions
- s diseaseAltzheimer'
- Registration Number
- JPRN-UMIN000027492
- Lead Sponsor
- Medical Corporation Kudoh Chiaki Neurosurgery Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with history of hypersensitivity to rivastigmine, components of donepezil hydrochloride or carbamate derivatives
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in serum BuChE activity, change in cognitive function severity evaluation (MMSE, ADAS-J) at registration, 3 months after administration, 6 months after administration
- Secondary Outcome Measures
Name Time Method TG, LDL, HDL, HbA1c, GOT, GPT, pancreatic amylase, MRI (VSRAD), blood pressure, pulsatility at the time of registration, 3 months after administration, 6 months after administration